Publications in collaboration with researchers from Dana–Farber Cancer Institute (14)

2023

  1. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

    Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687

  2. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615

2022

  1. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

    ESMO Open, Vol. 7, Núm. 5

  2. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060

  3. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

    The oncologist, Vol. 27, Núm. 12, pp. 1048-1057

2021

  1. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma

    The Journal of urology, Vol. 205, Núm. 2, pp. 414-419

2020

  1. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    The Lancet, Vol. 395, Núm. 10241, pp. 1907-1918

  2. Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 785-786

  3. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial

    ESMO Open, Vol. 5, Núm. 6

  4. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

    Cancer, Vol. 126, Núm. 18, pp. 4156-4167

2018

  1. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial

    Journal of Clinical Oncology

2017

  1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    The Lancet Oncology, Vol. 18, Núm. 11, pp. 1483-1492

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2014

  1. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

    International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16